, . Use the lowest dose of Aranesp necessary to avoid RBC transfusions. There are no clinically significant differences in the safety and efficacy of epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp), the two drugs most commonly used to treat anemia in cancer patients undergoing chemotherapy or radiation treatments, according to a new report by the Agency for Healthcare Research and Quality (AHRQ). b. In pregnant women, lactating women, neonates, and infants use only single-dose vials (the benzyl alcohol-free formulation) [see Contraindications (4) and Use in Specific Populations (8.1, 8.2, and 8.4)]. Peripheral blood progenitor cell (PBPC) collection: 10 mcg/kg/day or 5-8 mcg/kg twice daily in donors. 600 Units/kg intravenously weekly until completion of a chemotherapy course. If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose of RETACRIT . The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. (0.6MB), Anemia Assessment and Management Brochure, Pathophysiology of Anemia in Patients with CKD, * Case studies and patient profiles are hypothetical, WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE. A 30-day supply of Procrit costs well over $2,000 and prices for Epogen average around $600 per month. Aranesp and EPOGEN have not been shown to improve quality of life, fatigue, or patient well-being. Cardon Tablet Diclofenac, Excessive response: Hemoglobin increases >1 g/dL in any 2-week period: Decrease dose Hemoglobin increases and approaches the target value of 12 g/dL: Decrease weekly dosage by ~25%. More specifically, 23 patients in the epoetin alfa group
These are recommended
Sad Draft Horse Rescue Danazol, Do not dilute. Based on data from this CCHS DUE, darbepoetin alfa and
Severe chronic neutropenia: Congenital: 6 mcg/kg twice daily Idiopathic/cyclic: 5 mcg/kg/day, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9222, Supplied: Injection, solution [preservative free]: 300 mcg/mL (1 mL, 1.6 mL) [vial; contains sodium 0.035 mg/mL and sorbitol], Injection, solution [preservative free]: 600 mcg/mL (0.5 mL, 0.8 mL) [prefilled Singleject syringe; contains sodium 0.035 mg/mL and sorbitol], Drug UPDATES: ZARXIO - filgrastim-sndz injection [Drug information / PDF] Click link for the latest monographDosing: Click (+) next to Dosage and Administration section (drug info link). x\YGrI8$P[Co>, gdWTpHkYq|qTT8~?K7?0in70>l) |Knsw/dgo7v{}Gx\2vropiND{$a!2)e(H& We comply with the HONcode standard for trustworthy health information. /Type /Page
In patients who are receiving epoetin alfa once weekly, darbepoetin should be administered once every 2 weeks. (CKD) patients, darbepoetin alfa administered intravenously has
Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at even greater risk for cardiovascular reactions and mortality than other patients. alfa (Aranesp; Amgen) to be therapeutic equivalent products
alfa for chronic anemia of cancer and chemotherapy-induced anemia
Dosage SubQ: Adolescents >45 kg and Adults: 6 mg once per chemotherapy cycle; do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy; do not use in patients, infants, children, and smaller adolescents weighing <45 kg. 1152 0 obj
<>stream
endstream
endobj
1092 0 obj
<. In order to be included in the DUE,
Deep venous thrombosis prophylaxis is recommended during RETACRIT therapy [see Warnings and Precautions (5.1)]. Based on the patient's response, darbepoetin alfa may be administered as frequently as once every 3 or 4 weeks. endobj Existing patients on IV EPO, change to subcutaneous EPO using the . Production
G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation differentiation and selected end-cell functional activation (including enhanced phagocytic ability, priming of the cellular metabolism associated with respiratory burst antibody dependent killing, and the increased expression of some functions associated with cell surface antigens). About Contact Jobs. No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks. Non-hematopoietic pathologic changes observed in animals include fibrosis of tendons and joint capsules, periosteal thickening, papilledema, and embryotoxicity. Based on the patient's response, darbepoetin
Natural Antihistamine Supplement Zyloprim, for epoetin alfa-treated patients and 200 mcg every 2 weeks (or
Note: The manufacturer states that, until efficacy/toxicity parameters are established, the use of oprelvekin in pediatric patients (particularly those <12 years of age) should be restricted to use in controlled clinical trials. Available for Android and iOS devices. Please try after some time.Get new journal Tables of Contents sent right to your email inbox View important dosing
Obviously, everyone pays a different price, so when you talk about the cost of a drug at a given dose, you're always talking at least a little bit inaccurately, because most of your audience will be paying a slightly different price.Given the current choices (and now different Medicare-reimbursement standards) for erythropoietic stimulation, how do physicians make their treatment decisions?When asked about Procrit vs. Aranesp, Michael S. Gordon, MD, Associate Dean for Research at the University College of Medicine, Phoenix Campus, and Associate Director of the Arizona Cancer CenterGreater Phoenix Area, responded, What physicians always want is (1) a drug that works, or is better than, the standard that they have available; and (2) a drug that has fewer side effects or impacts their patients' quality of life less than the standard. The dose should be titrated to meet and
For patients who do not respond adequately over a 12-week escalation period, increasing the Aranesp dose further is unlikely to improve response and may increase risks. Adult Respiratory Distress Syndrome (ARDS) Adult respiratory distress syndrome (ARDS) has been reported in neutropenic patients with sepsis receiving Filgrastim, the parent compound of Neulasta, and is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. JKn&,&LzN deemed epoetin alfa (Procrit; OrthoBiotech) and darbepoetin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Aranesp, Epogen, Procrit, and Retacrit are proven when used to treat anemia in cancer chemotherapy when both of the following criteria are met: 1,4,5 Hematocrit less than 30% at initiation of therapy; and There is a minimum of two additional months of planned chemotherapy. 114 (n=92 CCF) patients were included in the DUE, 59 epoetin alfa
Studies of erythropoietin therapy
1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy ZARXIO is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4)]. Last updated on Jan 20, 2023. Previous dosage of epoetin alfa: 2500-4999 units/week, then darbepoetin alfa dosage: 12.5 mcg/week. IL-11 has also been shown to have non-hematopoietic activities in animals including the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis, inhibition of pro-inflammatory cytokine production by macrophages, and the stimulation of osteoclastogenesis and neurogenesis. The maximum number of administrations of Aranesp for a billing cycle is 5 times in 30/ 31days. Nephrologists are also very divided on whether it is easy to switch between long-acting ESAs (such as Amgen's Aranesp and Roche/Vifor's Mircera) and short-acting ESAs (such as Epogen and Retacrit . Aranesp, Epogen, Procrit, and Retacrit are proven and medically necessary when used to treat anemia in cancer . *. Monitor patients closely for new-onset seizures, premonitory symptoms, or change in seizure frequency. Response rates are defined
A total of
Do not use any vials or prefilled syringes exhibiting particulate matter or discoloration. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. >>
Discontinue treatment with oprelvekin >/= 2 days before starting the next planned cycle of chemotherapy. Previous dosage of epoetin alfa: 11,000-17,999 units/week,then darbepoetin alfa dosage: 40 mcg/week. /Metadata 71 0 R
Isoniazid Long-term Side Effects Provigil, in patients with chronic anemia of cancer as well as CIA document
Evaluate other causes of anemia. 7/2021: added Epogen (nonformulary). 600 Units/kg subcutaneously in 4 doses administered 21, 14, and 7 days before surgery and on the day of surgery. Approved by FMOLHS P&T. Medication Reference Drug or Biosimilar Formulary Status Preferred or Not preferred Automatic Therapeutic Interchange Discard unused portion of Aranesp in vials or prefilled syringes. David McAuley, Pharm.D. /Type /Catalog
When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability. IV
Discontinue Aranesp if responsiveness does not improve. Withhold RETACRIT if hemoglobin exceeds 12 g/dL. Drug class: Recombinant human erythropoietins. <>
Monitoring Parameters Complete blood count and platelet count should be obtained prior to chemotherapy. If the hemoglobin level exceeds 10 g/dL, reduce or interrupt the dose of Aranesp, and use the lowest dose of Aranesp sufficient to reduce the need for RBC transfusions. Drug class: Recombinant human erythropoietins. Trimethoprim/sulfamethoxazole Super P-force, Isotretinoin For Acne Herbolax, Do not mix with other drug solutions. Adults: 50 mcg/kg once daily for 10-21 days (until postnadir platelet count >/= 50,000 cells/uL). Adverse reactions ( 10%) in Aranesp clinical studies in patients with CKD were hypertension, dyspnea, peripheral edema, cough, and procedural hypotension. Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur with Aranesp or EPOGEN. How many biosimilars have been approved in the United States? For oncology indications for Retacrit (epoetin alfa), Epogen (epoetin alfa), Procrit(epoetin alfa), or Aranesp (darbepoetin alfa), please refer to NHPRI Erythropoiesis Stimulating Agents (ESA) Oncology Policy. 4 0 obj
These are recommended doses. of patients receiving transfusions was similar between the groups,
Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. Correction of anemia associated with cancer patients receiving chemotherapy: Initial: 2.25 mcg/kg SQ once weekly. PRCA: If severe anemia and low reticulocyte count develop during Aranesp treatment, withhold Aranesp and evaluate for PRCA (5.7). Sulfasalazine And Mesalamine Taken Together Aleve, A brochure to help you understand how to dose and administer Aranesp, and to convert from epoetin alfa to Aranesp in patients with anemia due to CKD. Single-dose vials of RETACRIT should be used only one time. Neumega is not indicated following myeloablative chemotherapy (see package insert for WARNINGS, Increased Toxicity Following Myeloablative Therapy). Adjust dose as follows to achieve and maintain a target hemoglobin: Inadequate response: Hemoglobin increases <1 g/dL after 6 weeks of therapy: Increase dose to 4.5 mcg/kg. If the hemoglobin rises rapidly (e.g., more than 1 g/dL in any 2-week period), reduce the dose of RETACRIT by 25% or more as needed to reduce rapid responses. 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation ZARXIO is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae e.g.febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3)]. administered less frequently. alfa is as well tolerated and efficacious as epoetin alfa even when
The intravenous route is recommended for patients on hemodialysis. OHSU's formulary erythropoiesis stimulating agent (ESA) is darbepoetin alfa (ARANESP). 5 0 obj
number of patients receiving transfusions, to increase hemoglobin
of Pharmacy Drug Information Center (216-444-6456, option #1). Adverse reactions ( 5%) in EPOGEN clinical studies in patients with CKD were hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, and upper respiratory tract infection. <>/Filter/FlateDecode/ID[<6A376E50FA41294D8BDE0DC442E05AF8>]/Index[1022 100]/Info 1021 0 R/Length 147/Prev 333934/Root 1023 0 R/Size 1122/Type/XRef/W[1 3 1]>>stream
The recommended starting dose for adult patients is 50 to 100 Units/kg 3 times weekly intravenously or subcutaneously. 1. The maximum number of administrations of Aranesp for a billing cycle is 5 Table of Contents CMS.gov. Previous dosage of epoetin alfa: 18,000-33,999 units/week,then darbepoetin alfa dosage: 60 mcg/week. Allergic Reactions Allergic reactions to Neulasta, including anaphylaxis, skin rash, and urticaria, have been reported in postmarketing experience. Preclinical trials have shown that mature megakaryocytes which develop during in vivo treatment with Neumega are ultrastructurally normal. 2.25 mcg/kg every week subcutaneously until completion of a chemotherapy course. Leukocytosis (white blood cell counts 100,000/mm3 ) has been observed in <1% of patients receiving pegfilgrastim. Estimate the starting weekly dose of Aranesp for adults and pediatric patients on the basis of the weekly epoetin alfa dose at the time of substitution (see Table 1). Administer Aranesp once every 2 weeks in patients who were receiving epoetin alfa once weekly. Conversion from Another ESA: dosed once monthly or once every two weeks based on total weekly epoetin alfa or darbepoetin alfa dose at time of conversion (2.2). In pediatric patients, Mircera is administered by intravenous injection only (2.2). Initiate RETACRIT treatment only when the hemoglobin level is less than 10 g/dL. Aranesp, Epogen, Procrit, and Retacrit are proven when used to treat anemia in cancer chemotherapy when both of the following criteria are met: 1,4,5. o Hematocrit less than 30% at initiation of therapy; and o There is a minimum of two additional months of planned chemotherapy . Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes fibroblasts, and endothelial cells. erythropoietin, darbepoetin alfa stimulates erythropoiesis.